Endocrine Protocol for Reversing Estrogenic & Prolactin-Induced Gynecomastia
The Clinical Gynecomastia Reversal Stack by Driada Medical is an advanced pharmacological intervention engineered to shrink glandular breast tissue and block multiple hormonal proliferation pathways simultaneously. When running intensive steroid cycles, an imbalance between circulating androgens, estrogens, and progestins can trigger painful subareolar glandular swelling. This bundle combines Raloxos (Raloxifene hydrochloride), Aromalyn (Exemestane), and Caberos (Cabergoline) to achieve targeted estrogen receptor antagonism in mammary tissue, non-reversible suicide inhibition of the aromatase enzyme, and potent dopamine receptor agonism to arrest prolactin-mediated growth.
Unlike non-selective approaches, Raloxifene exhibits superior binding affinity and tissue selectivity for breast tissue estrogen receptors without causing excessive systemic anti-estrogenic side effects. Concurrently, Exemestane permanently inactivates aromatase enzymes, eliminating estrogen rebound, while Cabergoline selectively agonises D2 receptors in the anterior pituitary to lower elevated prolactin levels. For athletes looking to avoid surgical excision or seeking comprehensive intervention, exploring dedicated ready PCT stacks provides an evidence-based roadmap to restore hormonal equilibrium and protect physical aesthetics.
Complete Bundle Contents & Compound Profiles
- 2 × Raloxos 30 mg (Raloxifene) | 50 tabs
- 1 × Aromalyn 25 mg (Exemestane) | 50 Tabs
- 1 × Caberos 0.125 mg (Cabergoline) | 20 Tabs
Clinical Anti-Gyno Administration Schedule
| Compound | Pack Quantity | Recommended Dosage | Duration (Weeks) |
|---|
| Raloxos 30 mg (Raloxifene) | 50 tabs | 2 × | 60 mg/day (10 days), then 30 mg/day (targeted breast-tissue SERM) | 1–8 |
| Aromalyn 25 mg (Exemestane) | 50 Tabs | 1 × | 12.5 mg every other day to eliminate circulating estradiol | 1–6 |
| Caberos 0.125 mg (Cabergoline) | 20 Tabs | 1 × | 0.25 mg twice weekly to suppress prolactin-induced flare-ups | 1–6 |
Administration Guidelines, Dosage Splitting & PCT Integration
Execution of this clinical protocol requires precise adherence to half-life pharmacokinetics. Raloxos (Raloxifene) is initiated at a loading dose of 60 mg daily for the first 10 days (split into 30 mg morning and evening with food), tapering to 30 mg daily through week 8. Aromalyn is taken at 12.5 mg every other day to clear excess circulating estradiol; learn more about managing estrogen levels with Aromasin (Exemestane). Caberos is dosed at 0.25 mg (two 0.125 mg tablets) twice weekly, ideally before bed to eliminate prolactin spikes and manage nocturnal hormonal pulses.
Consistent biological monitoring is critical while undergoing this reversal stack. A clinical test of testosterone and an estradiol assay should be performed around week 4 to avoid over-suppressing systemic estrogen, which can hinder lipid profiles and joint integrity. When progestogenic compounds like Nandrolone or Trenbolone triggered the issue, pharmaceutical-grade Cabergoline ensures rapid cessation of lactation and glandular tenderness. Once week 8 concludes, standard post-cycle therapy should proceed using your regular PCT calculator timelines to guarantee full hypothalamic-pituitary-gonadal axis normalization.
Key Advantages of the Driada Medical Gynecomastia Reversal Protocol
- Targeted Glandular Atrophy: Raloxifene provides superior selectivity over Tamoxifen, demonstrating up to an 86% clinical reduction in established glandular tissue without bone demineralisation.
- No Estrogen Rebound: Aromalyn works as an irreversible steroidal aromatase inactivator, preventing circulating estradiol flare-ups once the administration protocol is completed.
- Dual-Pathway Inhibition: The addition of Cabergoline arrests prolactin-induced ductal branching, eliminating nipple discharge, swelling, and hypersensitivity caused by 19-nor anabolic compounds.
- Lab-Verified Driada Purity: Every batch of Raloxos, Aromalyn, and Caberos is HPLC-tested to ensure accurate dosing and maximum pharmaceutical bioavailability across European athletic protocols.
Frequently Asked Questions
Can this stack reverse long-standing, fibrotic gynecomastia?
Raloxifene is scientifically proven to reduce pubertal and steroid-induced gynecomastia, even if present for several months. However, longstanding calcified or fibrotic tissue older than several years may only partially reduce, occasionally requiring surgical intervention if the glandular architecture has permanently matured.
Why is Exemestane preferred over Anastrozole in this bundle?
Exemestane is a suicidal aromatase inhibitor that permanently disables the aromatase enzyme. This prevents the rebound spike in estrogen that often occurs after discontinuing non-steroidal inhibitors like Anastrozole, protecting recovering breast tissue from sudden estrogen surges during protocol completion.
How should I dose Cabergoline to prevent nausea or dizziness?
Take 0.25 mg (two 0.125 mg tablets of Caberos) twice per week, spaced evenly (e.g., Monday and Thursday evenings). Taking your dose right before bed with a light snack significantly reduces transient dopamine-related side effects such as mild postural hypotension or nausea.
Do I need to stop my ongoing steroid cycle while using this stack?
While this protocol can be deployed on-cycle during severe flare-ups, optimal tissue reversal occurs in an environment where exogenous aromatizable and progestogenic compounds are discontinued or reduced to standard cruise/TRT doses, accelerating glandular involution.
Safety Notice: This bundle contains powerful endocrine modulators. Routine comprehensive blood work—including total and free testosterone testing, sensitive estradiol, and prolactin assays—is strongly recommended. Do not crush or chew coated tablets. Store in a cool, dry place away from direct light. Not for use by individuals under 18 years of age.
Raloxifene HCl 30 mg (x2 = 100 tabs) + Exemestane (Aromalyn) 25 mg + Cabergoline (Caberos) 0.5 mg, Driada Medical
